Pharsight

Cometriq is owned by Exelixis.

Cometriq contains Cabozantinib S-Malate.

Cometriq has a total of 7 drug patents out of which 0 drug patents have expired.

Cometriq was authorised for market use on 29 November, 2012.

Cometriq is available in capsule;oral dosage forms.

Cometriq can be used as method of treating medullary thyroid cancer.

The generics of Cometriq are possible to be released after 10 February, 2032.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7579473	EXELIXIS	c-Met modulators and methods of use	Aug, 2026 (3 years from now)
US11091439	EXELIXIS	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer	Jan, 2030 (6 years from now)
US8877776	EXELIXIS	(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	Oct, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11098015	EXELIXIS	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer	Jan, 2030 (6 years from now)
US11091440	EXELIXIS	Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer	Jan, 2030 (6 years from now)
US9717720	EXELIXIS	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds	Feb, 2032 (9 years from now)
US11298349	EXELIXIS	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds	Feb, 2032 (9 years from now)